Cerevel Therapeutics Holdings, Inc. Stock price

Equities

CERE

US15678U1280

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-28 pm EST 5-day change 1st Jan Change
41.22 USD -0.21% Intraday chart for Cerevel Therapeutics Holdings, Inc. +0.71% -2.78%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2024 * - Sales 2025 * - Capitalization 7.48B
Net income 2024 * -478M Net income 2025 * -548M EV / Sales 2024 * -
Net cash position 2024 * 709M Net cash position 2025 * 690M EV / Sales 2025 * -
P/E ratio 2024 *
-15.7 x
P/E ratio 2025 *
-14.6 x
Employees 321
Yield 2024 *
-
Yield 2025 *
-
Free-Float 41.99%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Cerevel Therapeutics Holdings, Inc.

1 day-0.21%
1 week+0.71%
Current month-1.62%
1 month-2.02%
3 months+64.95%
6 months+79.22%
Current year-2.78%
More quotes
1 week
40.85
Extreme 40.85
41.38
1 month
40.66
Extreme 40.66
43.59
Current year
40.66
Extreme 40.66
43.59
1 year
19.59
Extreme 19.59
43.59
3 years
12.01
Extreme 12.01
46.16
5 years
9.00
Extreme 9
46.16
10 years
9.00
Extreme 9
46.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 23-06-11
Director of Finance/CFO 43 23-05-14
Chairman 63 18-11-30
Members of the board TitleAgeSince
Director/Board Member 64 19-05-31
Director/Board Member 66 20-12-03
Director/Board Member 67 21-01-19
More insiders
Date Price Change Volume
24-02-28 41.22 -0.21% 609,810
24-02-27 41.3 +0.55% 1,050,878
24-02-26 41.08 +0.49% 1,433,330
24-02-23 40.88 -0.44% 1,028,297
24-02-22 41.06 +0.32% 2,060,210

Delayed Quote Nasdaq, February 28, 2024 at 04:00 pm EST

More quotes
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It is engaged in the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder and Parkinson's disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Its pipeline with various clinical trials underway or planned, including three ongoing Phase III trials and an open-label extension trial for tavapadon in Parkinson's, two planned Phase II trials and a planned open-label extension trial for emraclidine in schizophrenia and an ongoing Phase II proof-of-concept trial with an open-label extension trial for darigabat in focal epilepsy.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
41.22 USD
Average target price
44.78 USD
Spread / Average Target
+8.63%
Consensus
  1. Stock
  2. Equities
  3. Stock Cerevel Therapeutics Holdings, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW